BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA

SUMMARY – The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistant indolent NHL and CLL in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogeljić Patekar, Martina, Milunović, Vibor, Mišura Jakobac, Karla, Perica, Dražen, Mandac Rogulj, Inga, Kursar, Marin, Planinc-Peraica, Ana, Ostojić Kolonić, Slobodanka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536274/
https://www.ncbi.nlm.nih.gov/pubmed/31168188
http://dx.doi.org/10.20471/acc.2018.57.03.18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536274/
https://www.ncbi.nlm.nih.gov/pubmed/31168188
http://dx.doi.org/10.20471/acc.2018.57.03.18

Ejemplares similares